title: Results of a multicenter trial of the CapSure (Re/Stor) Continence shield on women with stress urinary incontinence.
abstract: OBJECTIVE
  To prospectively study the impact of the CapSure (Re/Stor) Continence shield for the treatment of stress urinary incontinence.
  
  
  METHODS
  One hundred women with pure stress urinary incontinence were enrolled in a 6-month study. Objective measures of urine loss included pad weight test (PdWt) and provocative stress test (PST). Subjective measures included incontinence diaries documenting the number of incontinence episodes per day (IEPD), quality of life questionnaires, and satisfaction surveys. Objective and subjective measures were performed prior to enrollment, during use of the CapSure shield, and after discontinuation of the device.
  
  
  RESULTS
  During the 12-week device utilization period, PdWt measurements demonstrated a 96% reduction in urine loss by week 1 and 97% by week 12. Eighty-two percent of subjects were completely dry by week 12. PST demonstrated 100% reduction in urine loss at each visit, with 91% of subjects completely dry by week 12. IEPD also demonstrated a 91% reduction in incontinence episodes by week 12. Quality of life scores and patient satisfaction surveys demonstrated significant improvement. During the 6-week post device utilization period (PUP), subjects continued to demonstrate a reduction in urine loss compared to pre-enrollment data, despite discontinuation of use. PdWt measurements demonstrated a 73% and 79% reduction in urine loss at weeks 14 and 18, respectively. Measurements of PST and IEPD demonstrated significant reductions in urine loss at weeks 14 and 18. A 1.5% prevalence of positive urine cultures was noted during device use. Bothersome vaginal or urethral irritation occurred in 12% of patients. Adverse events were few and required no therapeutic intervention.
  
  
  CONCLUSIONS
  The CapSure shield is a safe and efficacious method of managing stress urinary incontinence in women.
authors.affiliation: Department of Urology, University of Massachusetts Medical Center, Worcester, USA.
authors.forename: P
authors.initials: P
authors.lastname: Bellin
authors.forename: J
authors.initials: J
authors.lastname: Smith
authors.forename: W
authors.initials: W
authors.lastname: Poll
authors.forename: S
authors.initials: S
authors.lastname: Bogojavlensky
authors.forename: D
authors.initials: D
authors.lastname: Knoll
authors.forename: S
authors.initials: S
authors.lastname: Childs
authors.forename: J
authors.initials: J
authors.lastname: Tuttle
authors.forename: J
authors.initials: J
authors.lastname: Barada
authors.forename: J
authors.initials: J
authors.lastname: Dann
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001437:Bacteriuria / Q000382:microbiology; D004867:Equipment Design; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016496:Incontinence Pads; D008499:Medical Records; D008875:Middle Aged; D017060:Patient Satisfaction; D011312:Pressure; D015995:Prevalence; D011446:Prospective Studies; D011788:Quality of Life; D011795:Surveys and Questionnaires; D014526:Urethritis / Q000209:etiology; D014550:Urinary Incontinence, Stress / Q000628:therapy* / Q000652:urine; D014572:Urology / Q000295:instrumentation; D014627:Vaginitis / Q000209:etiology